Skip to content
The Policy VaultThe Policy Vault

Mycamine — CareFirst (Caremark)

Prophylaxis of Candida Infections in adult and pediatric patients age ≥ 4 months undergoing hematopoietic stem cell transplantation

Initial criteria

  • The safety and effectiveness of Mycamine have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed
  • Mycamine has not been adequately studied in patients with endocarditis, osteomyelitis, and meningoencephalitis due to Candida
  • The efficacy of Mycamine against infections caused by fungi other than Candida has not been established